FP045NOCTURNE: A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO COMPARE TOLVAPTAN (TLV) MODIFIED-RELEASE (MR) AND IMMEDIATE-RELEASE (IR) FORMULATIONS IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) PATIENTS (PT)